Regulora
Commercial- Indications
- Irritable bowel syndrome
Company intelligence / Profile preview
metaMe Health’s flagship product Regulora® received FDA clearance as a prescription digital therapeutic for abdominal pain associated with all forms of IBS. Regulora delivers gut-directed hypnotherapy via smartphone/tablet over seven 30-minute sessions across 12 weeks. Clinical studies of gut-directed hypnotherapy show response rates between 24% and 73%. The company has additional programs in development targeting other GI and chronic conditions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on metaMe Health.